中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

101 records (took 0.054 seconds)

    Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses
    45.
    发明授权
    Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses 失效
    使用已经失活的免疫原性免疫抑制和/或血管生成蛋白，其制备方法和药物或疫苗用途

    公开(公告)号：US07022482B2

    公开(公告)日：2006-04-04

    申请号：US10465645

    申请日：2003-06-20

    Applicant: Daniel A. Zagury ,  Jean-Francois Zagury

    Inventor： Daniel A. Zagury ,  Jean-Francois Zagury

    IPC: C12Q1/68

    CPC classification number: C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  C07K16/084 ,  C07K16/1036 ,  C07K16/1072 ,  C07K2319/21 ,  C07K2319/55 ,  C12N2710/20022 ,  C12N2740/14022 ,  C12N2740/16322

    Abstract: The invention concerns the use of a protein derived from cancer cells, virus-infected cells or immune-defence cells or a fragment of said protein, characterized in that said protein is initially an immunosuppressive and/or angiogenic protein with local activity and said properties are inactivated by at least 70%, through a physical and/or chemical treatment, by genetic recombination or by adjuvant conditioning, said treatment preserving its property of being identified by antibodies directed afainst said protein, and preserving sufficient immunogenic properties for generating antibodies neutralizing or blocking said native protein, to obtain a medicine for use as local anti-immnumosuppression and/or anti-angiogenic agent as an anticancer agent. The invention also concerns the resulting immunogenic compounds, their preparation method and their uses.

    Abstract translation: 本发明涉及使用衍生自癌细胞，病毒感染细胞或免疫防御细胞或所述蛋白质片段的蛋白质，其特征在于所述蛋白质最初是具有局部活性的免疫抑制和/或血管生成蛋白质，并且所述性质是 通过物理和/或化学处理，通过遗传重组或辅助调理灭活至少70％，所述处理保持其被定位在所述蛋白质上的抗体鉴定的性质，并保留足够的免疫原性以产生中和或阻断的抗体 所述天然蛋白质，以获得用作局部抗免疫抑制和/或抗血管生成剂作为抗癌剂的药物。 本发明还涉及所得的免疫原性化合物，其制备方法及其用途。

    Use of inactivated immunosuppressive or angiogenic immunogenic proteins for producing secretory IgA's
    46.
    发明授权
    Use of inactivated immunosuppressive or angiogenic immunogenic proteins for producing secretory IgA's 有权
    使用灭活的免疫抑制或血管生成免疫原性蛋白来产生分泌型IgA

    公开(公告)号：US07015016B2

    公开(公告)日：2006-03-21

    申请号：US10168115

    申请日：2000-12-14

    Applicant: Daniel Zagury

    Inventor： Daniel Zagury

    IPC: C12P21/06

    CPC classification number: C07K16/18 ,  A61K9/0043 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/541 ,  A61K2039/542 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55544 ,  A61K2039/55566 ,  A61K2039/585 ,  C07K16/1036 ,  C07K16/1063 ,  C12N2740/16034 ,  C12N2740/16134 ,  C12N2740/16334

    Abstract: The invention concerns the use of a protein derived from cancel cells, cells infected by a virus or immune cells or an inactive fragment of said protein, said protein being initially an immunosuppressive and/or an angiogenic protein with local activity whereof said properties have been inactivated by at least 70% by a physical and/or chemical treatment, such as formolisation, carboxamidation, carboxymethylation, maleimidation or oxidation by oxygen bubbling, by genetic recombination or by adjuvant conditioning, said treatment preserving its property of being identified by antibodies directed against said protein, and preserving sufficient immunogenic properties for generating antibodies neutralizing or blocking said native protein, or the use of a DNA molecule corresponding to said protein inactivated by mutation or to said inactive fragment, for obtaining a medicine designed to provide a patient with mucosal immunity based on secretion of IgA secretory antibodies, pharmaceutical compositions for the mucous membranes and IgA antibodies.

    Abstract translation: 本发明涉及来自消除细胞的蛋白质，由病毒或免疫细胞感染的细胞或所述蛋白质的无活性片段的用途，所述蛋白质最初是免疫抑制剂和/或具有局部活性的血管生成蛋白质，其中所述性质已被灭活 通过物理和/或化学处理如至少70％，通过基本重组或通过辅助调理来形成，例如甲酰化，羧甲酰化，羧甲基化，马来酰亚胺化或氧化，所述处理保持其被针对所述 蛋白质，并且保留足够的免疫原性，产生中和或阻断所述天然蛋白质的抗体，或使用对应于通过突变而灭活的所述蛋白质的DNA分子或所述非活性片段获得旨在为患者提供基于粘膜免疫的药物 对IgA分泌抗体的分泌，药物组合物 粘膜和IgA抗体的情况。

    HTLV-I/HTLV-II assay and method
    48.
    发明授权
    HTLV-I/HTLV-II assay and method 失效
    HTLV-I / HTLV-II测定法和方法

    公开(公告)号：US6110662A

    公开(公告)日：2000-08-29

    申请号：US236886

    申请日：1994-04-28

    Applicant: Steven K. H. Foung ,  Kenneth G. Hadlock ,  Theresa P. Chow

    Inventor： Steven K. H. Foung ,  Kenneth G. Hadlock ,  Theresa P. Chow

    IPC: G01N33/53 ,  C07K16/10 ,  C12P21/08 ,  G01N33/569 ,  G01N33/574 ,  G01N33/68 ,  C12Q1/70

    CPC classification number: C07K16/1036 ,  G01N33/56988 ,  G01N33/6854 ,  G01N2333/15 ,  Y10S435/81 ,  Y10S435/975

    Abstract: Method and assay kit for positively identifying HTLV-I and HTLV-II infection from human serum samples. The kit includes peptide antigens from the C-terminal regions of HLTV-I p19 and HTLV-II p21 gag proteins, and peptide antigens from the HLTV-I and HTLV-II env proteins immobilized on a solid support. After reaction of the serum sample with the solid support, an antibody-detection reagent in the kit is added to the support, to detect binding of human serum antibodies to each of the peptide antigens separately. The test allows positive identification of HTLV-I or HTLV-II when antibody binding to each HTLV-I or HTLV-II gag and env peptide antigen, respectively, is observed. Also disclosed is a kit for screening human sera for evidence of HTLV-I or HTLV-II infection.

    Abstract translation: 用于从人血清样品中阳性鉴定HTLV-1和HTLV-II感染的方法和测定试剂盒。 该试剂盒包括来自HLTV-I p19和HTLV-II p21 gag蛋白的C末端区域的肽抗原和固定在固体支持物上的来自HLTV-1和HTLV-II env蛋白的肽抗原。 在血清样品与固体支持物反应后，将试剂盒中的抗体检测试剂加入到载体中，以分别检测人血清抗体与每种肽抗原的结合。 当分别观察到抗体分别与每个HTLV-1或HTLV-II gag和env肽抗原结合时，该测试允许HTLV-1或HTLV-II的阳性鉴定。 还公开了用于筛选人血清以获得HTLV-1或HTLV-II感染证据的试剂盒。

Patent Agency Ranking